Profiel
Didier Pruneau worked as the Head of Pharmacology Department at Fournier Pharma SA, Head of Scientific Operations at Fovea Pharmaceuticals SA, and Head of Scientific Evaluation at Sanofi SA. He also served as the Chief Scientific Officer at Gensight Biologics SA from 2013 to 2018.
Pruneau holds a doctorate degree from the University of Dijon and graduate and doctorate degrees from Université de Paris 5 René Descartes.
Eerdere bekende functies van Didier Pruneau
Bedrijven | Functie | Einde |
---|---|---|
GENSIGHT BIOLOGICS S.A. | Hoofd Techniek/Wetenschap/O&O | 27-02-2018 |
Sanofi SA | Corporate Officer/Principal | - |
Fournier Pharma SA
Fournier Pharma SA Pharmaceuticals: MajorHealth Technology Fournier Pharma SA manufactures pharmaceutical products. The firm is also in the engaged in the research, development, production and marketing of molecules. The company has operations in Canada, China, Algeria, Bulgaria, Thailand and Turkey. It was founded in 1880 and is headquartered in Chenôve, France. | Corporate Officer/Principal | - |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Corporate Officer/Principal | - |
Opleiding van Didier Pruneau
University of Dijon | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
GENSIGHT BIOLOGICS S.A. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
Université de Paris 5 René Descartes | Consumer Services |
Fournier Pharma SA
Fournier Pharma SA Pharmaceuticals: MajorHealth Technology Fournier Pharma SA manufactures pharmaceutical products. The firm is also in the engaged in the research, development, production and marketing of molecules. The company has operations in Canada, China, Algeria, Bulgaria, Thailand and Turkey. It was founded in 1880 and is headquartered in Chenôve, France. | Health Technology |
Sanofi SA | Health Technology |